Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 7/20 | 0.54 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.51 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | CBFB | Q13951 | 1/20 | 0.49 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.48 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | ATP4A | P20648 | 1/20 | 0.44 |
| ▸ | ATP4B | P51164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23782321 | 0.87 | NPBWR1 (0.40) | NPBWR1DGAT1KCNH2ADAMTS5DYRK1A | |
| SCHEMBL29954586 | 0.78 | ALPL (0.51) | ADAMTS5CBFBHRH4EGLN1 | |
| SCHEMBL1335316 | 0.78 | ALPL (0.51) | ADAMTS5CBFBHRH4EGLN1 | |
| SCHEMBL29957236 | 0.77 | RUNX1 (0.52) | CBFBSCN10AEGLN1 | |
| SCHEMBL18765107 | 0.77 | RUNX1 (0.52) | CBFBSCN10AEGLN1 | |
| SCHEMBL10694441 | 0.76 | KDM4E (0.65) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B | |
| SCHEMBL29953188 | 0.75 | MAPT (0.57) | ADAMTS5HRH4GAAMAPT | |
| SCHEMBL29951153 | 0.75 | ALDH1A1 (0.51) | MAPTEGLN1 | |
| SCHEMBL21500616 | 0.75 | NPBWR1 (0.58) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B | |
| SCHEMBL2107034 | 0.75 | NPBWR1 (0.58) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376473-A1 | PRMTS INHIBITOR AND USE THEREOF | CYTOSINLAB THERAPEUTICS CO LTD (CN) | 2025-12-11 | — | — | US | disclosed |
| EP-4549440-A1 | CLASS OF PRMT5 INHIBITORS AND USE THEREOF | Cytosinlab Therapeutics Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| EP-4549442-A1 | PRMT5 INHIBITORS AND USE THEREOF | Cytosinlab Therapeutics Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-119562954-A | PRMT5 inhibitor and application thereof | 上海赛岚生物科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119487041-A | PRMT5 inhibitor and application thereof | 上海赛岚生物科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240376126-A1 | PRMT5 INHIBITOR AND THE USE THEREOF | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2024-11-14 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376126-A1 | PRMT5 INHIBITOR AND THE USE THEREOF | PRMT5, PRMT1, PRMT6 | NPBWR1 4686/4885DGAT1 2261/4885KCNH2 4411/4885 |
| US-20250376473-A1 | PRMTS INHIBITOR AND USE THEREOF | PRMT5, PRMT1, PRMT6 | NPBWR1 4623/4885DGAT1 3047/4885KCNH2 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.